BIO-key International Inc. BKYI
1.79
(0.25)
(12.25%)
as of 25 Sep
- Market cap
- $2.9M
- P/E
- 0.0×
Follow BKYI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.70 | 0.85 | 0.60 | 0.75 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.53) | (15.32) | (1.96) | (4.22) | |
P/B ratio |
1.08 | 1.12 | 0.70 | 0.78 | |
Price to Tangible BV |
1.29 | 1.33 | 0.84 | 0.92 | |
EV/Sales |
0.64 | 0.66 | 0.33 | 0.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.04) | (1.01) | (0.42) | (1.13) | |
EV/FCF |
(0.70) | (0.69) | (0.29) | (0.71) | |
Quick Ratio |
1.03 | 1.20 | 1.26 | 1.01 | |
Current Ratio |
1.26 | 1.41 | 1.47 | 1.26 | |
Net Debt/EBITDA |
3.45 | 85.66 | 0.66 | 1.34 | |
Debt/Assets |
0.17% | 0.15% | 0.61% | 10.76% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.18 | |
Asset Turnover |
0.74 | 0.67 | 0.70 | 0.77 | |
Operating CF/Net income |
1.47 | 1.75 | 0.43 | 1.16 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
33.35% | 28.75% | 64.08% | 44.11% | |
Selling, General and Administrative Expense of Revenue |
81.41% | 61.06% | 168.75% | 90.36% | |
Intangible Assets out of Total Assets |
0.10 | 0.09 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
2.22% | 1.90% | 3.75% | 2.05% | |
Graham Net Nets |
0.14 | 0.22 | 0.37 | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(176.08%) | (177.00%) | (200.58%) | (144.44%) | |
Free Cash Flow Yield |
(131.88%) | (113.08%) | (186.10%) | (112.79%) | |
Revenue per Share |
1.85 | 2.07 | 1.63 | 2.35 | |
Operating CF per Share |
(0.82) | (0.35) | (2.75) | (1.70) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.82) | (0.35) | (2.76) | (1.71) | |
Cash per Share |
1.33 | 2.17 | 4.05 | 3.10 | |
Shareholders Equity per Share |
4.18 | 4.73 | 7.68 | 9.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.18 | 4.73 | 7.68 | 9.18 | |
Free Cash Flow |
(0.85) | (0.36) | (1.84) | (1.12) | |
Working Capital |
0.79 | 1.30 | 1.44 | 0.78 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
0.66 | 1.22 | 1.34 | (0.32) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(30.05%) | (9.55%) | (395.76%) | (62.26%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.43 | 1.21 | 1.01 | 0.50 | |
Average Payables |
0.65 | 0.54 | 0.66 | 1.11 | |
Average Inventory |
0.35 | 0.35 | 0.37 | 0.39 | |
Average Assets |
9.00 | 9.67 | 8.46 | 8.26 | |
Average Common Equity |
5.59 | 6.21 | 4.44 | 3.09 |
Columns are period end dates